__timestamp | Dyne Therapeutics, Inc. | Travere Therapeutics, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 1145000000 | 570979 |
Thursday, January 1, 2015 | 2028000000 | 2185000 |
Friday, January 1, 2016 | 2281000000 | 4554000 |
Sunday, January 1, 2017 | 2932000000 | 3605000 |
Monday, January 1, 2018 | 24000 | 5527000 |
Tuesday, January 1, 2019 | 271000 | 5234000 |
Wednesday, January 1, 2020 | 700000 | 6126000 |
Friday, January 1, 2021 | 1088000 | 6784000 |
Saturday, January 1, 2022 | 3345000 | 7592000 |
Sunday, January 1, 2023 | 2461000 | 11450000 |
In pursuit of knowledge
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the annual cost of revenue trends for Travere Therapeutics, Inc. and Dyne Therapeutics, Inc. from 2014 to 2023.
Travere Therapeutics has shown a steady increase in its cost of revenue, peaking in 2023 with a 100% rise from its 2014 figures. This growth reflects the company's expanding operations and investment in research and development. In contrast, Dyne Therapeutics experienced a volatile trajectory, with a significant spike in 2017, followed by a sharp decline in subsequent years. By 2023, Dyne's costs had reduced by over 99% from their 2017 peak, indicating strategic cost management or shifts in operational focus.
These insights provide a window into the financial strategies of these biotech leaders, offering valuable perspectives for potential investors.
Pfizer Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Bio-Techne Corporation vs Dyne Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Dyne Therapeutics, Inc.
Cost of Revenue: Key Insights for Sarepta Therapeutics, Inc. and Dyne Therapeutics, Inc.
Cost of Revenue Trends: Exelixis, Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs Dyne Therapeutics, Inc.
Pharming Group N.V. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Analyzing Cost of Revenue: MorphoSys AG and Travere Therapeutics, Inc.
Cost of Revenue Comparison: Geron Corporation vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Travere Therapeutics, Inc. vs Galapagos NV
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses